- Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
- Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024
- Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
- Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
- Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
- Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité
- Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
- Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
More ▼
Key statistics
On Thursday, Inventiva SA (IVA:PAR) closed at 3.33, 33.00% above the 52 week low of 2.50 set on May 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.30 |
---|---|
High | 3.44 |
Low | 3.30 |
Bid | 3.30 |
Offer | 3.36 |
Previous close | 3.28 |
Average volume | 54.51k |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 172.13m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of May 23 2024 16:27 BST.
More ▼